European anticoagulants market is estimated to grow at a CAGR of 6.6% during the forecast period. Rising prevalence of heart diseases is the major factor accelerating the market growth. As per the 2019 report from the European Society of Cardiology (ESC) Atlas, over 6 million new CVD cases reported in the EU. With nearly 49 million people suffering from CVD in the EU, it cost to the EU economies is high at nearly $255 billion annually. This, in turn, is resulting in an increasing demand for anticoagulants medicines used to prevent the blood from clotting as rapidly or as potentially as normal. Anticoagulants are also known as blood thinners. These medications are used for the treatment and prevention of blood clots that may occur in the blood vessels. Therefore, anticoagulants are utilized for the prevention of blood clots and atrial fibrillation (AF) is the most common condition in which blood clots are formed.
Get Free Sample link @ https://www.omrglobal.com/request-sample/european-anticoagulants-market
The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). The use of novel oral anticoagulants (NOACs) is growing significantly in Europe owing to their advantages over older drugs including warfarin. NOACs has demonstrated tremendous safety and efficacy without the requirement of subsequent dose adjustment and frequent monitoring. Based on application, the market is classified into pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others.
A full report of European Anticoagulants Market available @ https://www.omrglobal.com/industry-reports/european-anticoagulants-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
European Anticoagulants Market by Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
European Anticoagulants Market by Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
Regional Analysis
- UK
- Germany
- France
- Spain
- Italy
- Rest of European
Company Profiles
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol Myers Squibb Co.
- Daiichi Sankyo Company, Ltd.
- GlaxoSmithKline plc
- Mylan N.V.
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
The Report Covers
- Comprehensive research methodology of the European anticoagulants market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European anticoagulants market.
- Insights about market determinants that are stimulating the European anticoagulants market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-anticoagulants-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
